NASDAQ:RGLS • US75915K3095
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REGULUS THERAPEUTICS INC (RGLS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-05-01 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-04-30 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-04-30 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-04-30 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-03-27 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2025-03-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-14 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-06-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-31 | Jones Trading | Initiate | Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-19 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-18 | Leerink Partners | Initiate | Outperform |
| 2024-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-13 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2023-09-21 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 72K | 6.832M 9,388.89% | 10.006M 46.46% | -100.00% | 90.168M | 342.28M 279.60% | 700.62M 104.69% | 1.393B 98.82% | 258.06M -81.47% | ||||||
| EBITDA YoY % growth | -44.501M 34.18% | -15.903M 64.26% | -13.688M 13.93% | N/A -99.86% | N/A -2.78% | -31.314M -9.83% | -50.898M -60.91% | -63.24M -27.26% | -86.7M -37.10% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -46.763M 33.32% | -16.834M 64.00% | -14.155M 15.91% | -28.069M -96.51% | -29.407M -1.52% | -31.569M -10.16% | -51.837M -60.85% | -56.692M -13.29% | -72.72M -28.27% | 18.88M 125.96% | 243.25M 1,188.40% | 561.75M 130.94% | 1.18B 110.06% | 103.02M -91.27% | |
| Operating Margin | -64,948.61% | -246.40% | -141.47% | N/A | N/A | N/A | N/A | N/A | N/A | 20.94% | 71.07% | 80.18% | 84.71% | 39.92% | |
| EPS YoY % growth | -55.20 58.56% | -11.00 80.07% | -5.50 50.00% | -3.33 40.00% | -1.80 42.42% | -1.62 16.32% | -0.87 45.28% | -0.92 -5.52% | -1.08 -17.56% | -0.12 88.66% | 1.76 1,537.50% | 4.23 140.58% | 8.48 100.24% | N/A |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 -27.20% | -0.26 -21.43% | -0.27 -34.64% | -0.28 -83.60% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.251M -16.24% | -16.948M -11.43% | -18.063M -31.41% | -14.215M -34.89% |
All data in USD
12 analysts have analysed RGLS and the average price target is 8.67 USD. This implies a price increase of 6.25% is expected in the next year compared to the current price of 8.16.
REGULUS THERAPEUTICS INC (RGLS) will report earnings on 2025-08-06, after the market close.
The consensus EPS estimate for the next earnings of REGULUS THERAPEUTICS INC (RGLS) is -0.22 USD and the consensus revenue estimate is 0 USD.
The consensus rating for REGULUS THERAPEUTICS INC (RGLS) is 73.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.